WUXI APPTEC
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for s... mall molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".
WUXI APPTEC
Industry:
Biotechnology Health Care Medical Device Outsourcing Pharmaceutical
Founded:
2000-12-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.wuxiapptec.com
Total Employee:
10001+
Status:
Active
Contact:
651-675-2000
Total Funding:
1.59 B USD
Technology used in webpage:
SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving Global Site Tag Nginx Sitelinks Search Box Amazon
Similar Organizations
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
Current Employees Featured
Shuhui Chen Chief Scientific Officer @ WuXi AppTec
Chief Scientific Officer
Peter Tong Chief Operating Officer @ WuXi AppTec
Chief Operating Officer
Ge Li Founder, Chairman and CEO @ WuXi AppTec
Founder, Chairman and CEO
2008-01-01
RJ Fitch Vice President Operations & General Manager @ WuXi AppTec
Vice President Operations & General Manager
2016-01-01
Zhaohui Zhang Senior Vice President of Operations @ WuXi AppTec
Senior Vice President of Operations
Steve Yang Co-CEO @ WuXi AppTec
Co-CEO
Edward Hu Co-CEO @ WuXi AppTec
Co-CEO
2018-08-01
Ellis Chu Chief Financial Officer @ WuXi AppTec
Chief Financial Officer
2019-01-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-01 | Oxford Genetics | Oxford Genetics acquired by WuXi AppTec | N/A |
| 2019-05-05 | Pharmapace | Pharmapace acquired by WuXi AppTec | N/A |
| 2017-10-17 | ResearchPoint Global | ResearchPoint Global acquired by WuXi AppTec | N/A |
| 2017-01-19 | HD Biosciences | HD Biosciences acquired by WuXi AppTec | N/A |
| 2016-04-15 | Crelux | Crelux acquired by WuXi AppTec | N/A |
| 2015-01-09 | NextCODE Health | NextCODE Health acquired by WuXi AppTec | 65 M USD |
Investors List
Ping An Bank
Ping An Bank investment in Debt Financing - WuXi AppTec
Warburg Pincus
Warburg Pincus investment in Post-IPO Equity - WuXi AppTec
Eight Roads Ventures
Eight Roads Ventures investment in Series C - WuXi AppTec
Eight Roads Ventures
Eight Roads Ventures investment in Series B - WuXi AppTec
Eight Roads Ventures
Eight Roads Ventures investment in Series A - WuXi AppTec
NewSpring
NewSpring investment in Venture Round - WuXi AppTec
Commerce Health Capital
Commerce Health Capital investment in Venture Round - WuXi AppTec
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-10-20 | ShouTi | WuXi AppTec investment in Series B - ShouTi | 100 M USD |
| 2021-06-03 | Stemirna | WuXi AppTec investment in Venture Round - Stemirna | 1.2 B CNY |
| 2021-05-28 | MegaRobo | WuXi AppTec investment in Corporate Round - MegaRobo | 65 M USD |
| 2021-05-26 | Engine Biosciences | WuXi AppTec investment in Series A - Engine Biosciences | 43 M USD |
| 2021-05-10 | OakMega | WuXi AppTec investment in Series A - OakMega | N/A |
| 2021-02-22 | AnchorDx | WuXi AppTec investment in Series C - AnchorDx | 40 M USD |
| 2021-02-09 | Drug Farm | WuXi AppTec investment in Series A - Drug Farm | 56 M USD |
| 2020-11-17 | D3 Bio | WuXi AppTec investment in Series A - D3 Bio | 200 M USD |
| 2020-06-11 | JW Therapeutics | WuXi AppTec investment in Series B - JW Therapeutics | 100 M USD |
| 2020-05-26 | Insitro | WuXi AppTec investment in Series B - Insitro | 143 M USD |
Newest Events participated
Participated in BioProcess International West 2017
on 2017-02-27 as sponsor
Official Site Inspections
http://www.wuxiapptec.com Semrush global rank: 819.81 K Semrush visits lastest month: 47.12 K
- Host name: 48.211.129.204
- IP address: 48.211.129.204
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "WuXi AppTec"
WuXi AppTec: Enabling Innovation
WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating. Shanghai, November 20, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and …See details»
Every drug can be made and every disease can be treated - WuXi …
Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping …See details»
Home | WuXi AppTec
Mit seinen einzigartigen Geschäftsmodellen bietet WuXi AppTec integrierte End-to-End-Services wie CRDMO (Contract Research, Development and Manufacturing Organization) für chemische Arzneimittel, Biologieforschung, …See details»
2024Q3media package AT EN - officialsite-static.wuxiapptec.com
Sep 30, 2024 2023/11/09 WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan 2023/10/30 WuXi …See details»
Wuxi City, China - STA Facility | WuXi STA
Shanghai, China, July 17, 2023 -- WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today launched its first ... Read More. WuXi STA Launches First Continuous Manufacturing Line for …See details»
WuXi Testing | WuXi AppTec
•SMO (SMO- Site Management Organization) •Patient Recruitment •Site Start-up •ARO (Academic Research Organization) WuXi MedKey focuses on the SMO on-site execution of clinical studies. We have more than 4,000 CRCs in over 160 …See details»
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in …
6 days ago Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing …See details»
WuXi STA Breaks Ground for New Pharmaceutical …
Aug 16, 2022 As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, …See details»
News - WuXi AppTec
WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore. The company …See details»
WuXi STA Opens Oligonucleotide Large-Scale …
Jan 2, 2020 In addition, the company’s industry-leading small molecule process chemistry organization adds further value in handling complex conjugation chemistry that involves oligonucleotide and other molecular modalities, as well …See details»
WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility …
Feb 2, 2021 The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s …See details»
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI, January 12, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life …See details»
WuXi AppTec Signs Definitive Agreement to Sell U.S. Medical …
SHANGHAI, January 17, 2025 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life …See details»
WuXi AppTec Listed in TIME Magazine's World's Best Companies …
Shanghai, January 3, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences …See details»
Taixing, China - STA Facility | WuXi TIDES - tides.wuxiapptec.com
The 169-acre site offers API manufacturing for oligonucleotides, peptides & conjugates at any scale. When combining the peptide capacity in our Changzhou site, the total reactor volume of …See details»
Despite External Challenges, WuXi AppTec Revenue and Profit …
Sep 30, 2024 WuXi Testing: Drug Safety Evaluation Service & Site Management Organization (SMO) Maintain Leading Positions · Q1-Q3 revenue of WuXi Testing reached RMB4.62 billion. …See details»
WuXi AppTec Code of Business Conduct and Ethics
- Reporting mailbox: InternalAudit@wuxiapptec.com ; - Reporting hotline: 86-400-820-6869; or - Ding Talk ："Compliance Report". North America, Europe, Israel and UK: - The head of your …See details»
WuXi AppTec offers rosy 2025 guidance despite US-China tensions
3 days ago WuXi AppTec contract research organization contract manufacturing organization China With the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the …See details»
WuXi Advanced Therapies Launches New World-Class AAV
January 13, 2020 – Philadelphia, PA - WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services …See details»
Press Releases - wuxiapptec.com
SHANGHAI, October 29, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life …See details»